ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2026; 16(3): 229-235


An LC–MS/MS method development and validation for the quantification of selpercatinib in spiked human K2EDTA plasma

Prathusha Katthala, G. Shiva Kumar.



Abstract
Download PDF Post

An LC-MS/MS method is needed to accurately measure the concentration of selpercatinib in a biological sample. This method should be both specific and sensitive. The processed materials were separated using a Zorbax SB-C18 column (50 mm × 4.6 mm) 3.5 μm with a mobile phase of acetonitrile, methanol, and 0.1% HCOOH in the proportion of 20:70:10. The mobile phase was measured using a column with 0.7ml/minute rate of flow. The drug and internal standard, ibrutinib were assessed by monitoring the transitions of m/z –526.25/450.16 and 441.20/55.01 for selpercatinib and IS, correspondingly, in multiple reaction monitoring mode. The linearity line and correlation coefficient (r2) values were y = 0.0012x - 0.0378 and >0.99, correspondingly. For the QC samples (253, 1,800, and 2,700 ng/ml), the %RSD of inter and intraday precision of the developed method ranged from 2.41% to 5.23%. The proposed method was developed and validated as per the regulatory guidelines.

Key words: Selpercatinib, Cancer, LC-MS/MS, Linearity, Accuracy.







Bibliomed Article Statistics

5
R
E
A
D
S

1
D
O
W
N
L
O
A
D
S
02
2026

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.